Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Haleon PLC Sponsored ADR (HLN) vs Neurocrine Biosciences, Inc. (NBIX)

Haleon PLC Sponsored ADR and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Haleon PLC Sponsored ADR is the larger, with a market value of $40.3B against $14.1B — 2.9× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.6× against 20.6×. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 13.8%) and the higher return on invested capital (15.0% vs 0.00%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 14 and Haleon PLC Sponsored ADR on 7.

Valuation

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
P/E 20.64 19.63 20.14
P/S 2.35 4.14 2.25
P/B 1.93 3.78 1.90
Price to free cash flow 9.36 16.06 16.54
EV/EBITDA 12.36 16.65 12.29
EV/Sales 2.90 4.11 2.56
Earnings yield 4.84% 5.09% (2.99%)
Free cash flow yield 10.68% 6.23% 0.00%

Profitability

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Gross margin 62.22% 97.94% 53.94%
Operating margin 17.93% 23.56% 0.00%
Net margin 13.79% 20.91% 0.00%
Free cash flow margin 0.00% 25.80% 0.00%
Return on equity 0.00% 22.09% (0.40%)
Return on assets 0.00% 15.26% (3.32%)
Return on invested capital 0.00% 15.04% 0.00%

Growth

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 34.42% 10.01%
EPS growth (last fiscal year) 22.50% 41.95% —
Revenue growth, 5-year CAGR 1.43% 22.29% 6.74%
Net income growth, 5-year CAGR 6.98% 3.28% 0.00%

Health

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.00 0.05
Current ratio 0.69 1.87 2.31
Net debt to EBITDA 2.63 (2.33) 0.85

Dividend

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Dividend yield 1.70% — 1.70%
Payout ratio — 0.00 0.00

Size

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Market cap 40.28b 14.12b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack